Navigation Links
Pharmathene Reports Third Quarter 2008 Financial and Operational Results
Date:11/13/2008

ANNAPOLIS, Md., Nov. 13 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter and nine months ended September 30, 2008.

For the third quarter of 2008, PharmAthene recognized revenues of $10.7 million compared to $3.4 million in the same period of 2007. For the nine months ended September 30, 2008 and 2007, the Company reported revenues of $27.4 million and $8.7 million, respectively. These revenues consisted primarily of contract funding from the U.S. government for the development of the Company's medical countermeasures, Protexia(R), SparVax(TM) and RypVax(TM). As a result of the Avecia vaccines acquisition in the second quarter of 2008, and particularly the acquired U.S. government contracts supporting the development of the rPA anthrax vaccines and RypVax(TM) plague vaccine product candidates, revenues for the three and nine month periods ended September 30, 2008 were further boosted by $5.5 million and $8.9 million, respectively.

Research and development expenses were $9.4 million and $3.6 million for the quarter ended September 30, 2008 and 2007, respectively. For the nine months ended September 30, 2008 and 2007, research and development expenses were $26.5 million and $10.7 million, respectively. Expenses for the third quarter and nine months of 2008 resulted from research and development activities related to programs for Valortim(R) and Protexia(R) as well as expenses related to the Company's SparVax(TM) and RypVax(TM) programs, which were acquired in the second quarter of 2008. The increase in research and development expenses is primarily due to process development expenses, manufacturing activities and clinical development expenses related to the Company's programs.

General and administrative expenses for the Company were $4.8 million and $3.2 m
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
2. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
3. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
4. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
5. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
6. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
7. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
8. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
9. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
10. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
11. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... MADISON, N.J. , Aug. 27, 2014 /PRNewswire/ ... significant potential to help physicians better identify early-stage ... progression and disability, according to a new study ... from Quest Diagnostics (NYSE: DGX ) ... of the 14-3-3eta protein outperformed conventional antibody-serum testing, ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com ... The Graphene Opportunity - A Rational View ... Graphene The New Nanotech? A similar amount ... of applications ranging from microelectronics to water treatment, ... announced the availability of the Graphene Opportunity Report, ...
(Date:8/27/2014)... Research and Markets  has announced the addition of ... Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... spectrometer industry. The report provides a basic ... industry chain structure. The isotope ratio mass spectrometer market ...
(Date:8/27/2014)... 27, 2014 Riviera Beach, Florida ... the creation of the Sancilio Scientific Advisory Board ... SCI’s philosophy of looking to nature for pharmaceutical ... actions are based on sound scientific data, analyses, ... Board provides a vehicle for SCI to receive ...
Breaking Biology Technology:Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3
... 26, 2011 Reportlinker.com announces that ... is available in its catalogue: ... Strategies - A Guide to ... and Biopharmaceutical Industries ...
... Our understanding of what differentiates cancer cells from normal cells ... complex signal systems of individual cells. By combing two different ... research world with a tool for studying signal paths on ... published today in PLoS One . "We also ...
... In the wake of the March 11 earthquake and ... across Japan, the award-winning undergraduate internship program NanoJapan is ... rather than having U.S. undergraduates travel to Japan for ... the opportunity to send 25-30 students to Rice University ...
Cached Biology Technology:Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 2Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 3Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 4Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 5Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 6Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 7Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 8Reportlinker Adds Technology Transfer Strategies - A Guide to Maximizing Returns Within the Pharmaceutical and Biopharmaceutical Industries 9Combo method reveals cells' signal systems 2Reverse NanoJapan: Rice to host 25-30 Japanese students 2
(Date:8/27/2014)... circuits in the brain of mice, scientists have ... research, led by Howard Hughes Medical Institute investigator ... (MIT), reveals that the connections between the part ... an experience and the part of the brain ... are malleable. , Altering those connections can ...
(Date:8/27/2014)... pathogens posing the greatest risk to Europe based upon ... of Liverpool researchers using a ,big data, approach to ... of Infection and Global Health ranked the top 100 ... animals using a system which, they believe, will help ... the spread of infectious diseases, including as a result ...
(Date:8/27/2014)... available in German . ... most common inherited disease affecting the peripheral nervous system. ... Planck Institute of Experimental Medicine and University Medical Centre ... is impaired in rats with the disease. These cells ... as myelin, which facilitates the rapid transfer of electrical ...
Breaking Biology News(10 mins):Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4Big data approach identifies Europe's most dangerous human and domestic animal pathogens 2Potential therapy for incurable Charcot-Marie-Tooth disease 2
... and wild--are indifferent to sweets. A new study ... their strictly carnivorous behavior. "We took a behavioral ... senior author of the study and Associate Director ... on mammalian tongues are specialized taste bud receptors ...
... invaluable decision-making tools for public health officials. As ... 2001, models can be useful in two ways: ... infection and they can allow the comparison of ... implicit assumptions that may systematically bias their predictions, ...
... of Massachusetts Amherst have discovered a tiny biological ... helps describe how microorganisms can clean up groundwater ... also have applications in the emerging field of ... extremely small dimensions. , The findings of microbiologist ...
Cached Biology News:Field of beams - Novel system uses polarized light pulses to reveal crop health 2Researchers Discover That Microbes Can Produce Miniature Electrical Wires 2Researchers Discover That Microbes Can Produce Miniature Electrical Wires 3Researchers Discover That Microbes Can Produce Miniature Electrical Wires 4
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
...
Biology Products: